Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Receivables (2022 - 2025)

Spero Therapeutics' Receivables history spans 4 years, with the latest figure at $25.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 51.62% year-over-year to $25.4 million; the TTM value through Dec 2025 reached $25.4 million, down 51.62%, while the annual FY2025 figure was $25.4 million, 51.62% down from the prior year.
  • Receivables reached $25.4 million in Q4 2025 per SPRO's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $55.5 million in Q2 2024 to a low of $1.1 million in Q4 2022.
  • Average Receivables over 4 years is $34.6 million, with a median of $38.8 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 4576.85% in 2023, then crashed 95.38% in 2025.
  • A 4-year view of Receivables shows it stood at $1.1 million in 2022, then soared by 4576.85% to $50.7 million in 2023, then rose by 3.51% to $52.5 million in 2024, then tumbled by 51.62% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Receivables are $25.4 million (Q4 2025), $2.5 million (Q3 2025), and $26.9 million (Q2 2025).